Vertex Expands In Vivo Gene-Editing Plans With Verve Liver Disease Pact

Complements Presence In Ex Vivo And Cell Therapy

 
• By Andrew McConaghie
Vertex Mobile
Vertex is investing in cell therapy and ex vivo and in vivo gene editing platforms. • Source: Shutterstock

More from Business

More from Scrip